Program
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636
Its studies are mostly in Breast Neoplasms, led by Ensem Therapeutics.
Furthest: phase 2, since May 1, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ensem Therapeutics | 11 open or running | phase 2since May 1, 2025 | May 1, 2025 | Jun 30, 2027phase 2 · NCT06993844 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 1, 2025First study: phase 2 study in NeoplasmsFirst studyNCT06993844 · 233 planned · United States, China
Ahead
- Jun 30, 2027Primary completion: phase 2 study in NeoplasmsNCT06993844
TargetBeta
PIK3CA →read by rule
“An orally bioavailable, pan-mutant selective inhibitor and degrader of the catalytic subunit of class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) alpha (phosphoinositide 3-kinase alpha; PIK3CA; PI3K p110alpha), ”NCIt, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 37 |
| inavolisibrule | Hoffmann-La Roche | phase 3 | 20 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| serabelisibrule | Takeda | phase 2 | 11 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06993844Neoplasms · United States, China | 2 | Recruiting | Jun 30, 2027 | 233 |
How it is read
Names in the registry
- “ETX-636 dose escalation”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.